- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Sa | ESMO: Chasing Keytruda, AstraZeneca's Imfinzi pitches its own Padcev combos in bladder cancer | ||
| Sa | ESMO: Amgen's Imdelltra drives massive survival benefit in 'watershed moment' for small cell lung cancer | ||
| Sa | Bayer's Nubeqa scores phase 3 win in high-risk prostate cancer | ||
| Sa | The Oral GLP-1 Tracker: Foundayo, Wegovy pill take slight dip amid holiday week | ||
| Fr | Biopharma Companies Must Break the DMTA Linearity | ||
| Fr | Argenx confirmatory trial update for Vyvgart puts small dent in strong Q3 | ||
| Fr | Gilead to pay $45M as it settles Medicaid kickback allegations from Texas AG Paxton | ||
| Fr | GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing | ||
| Fr | Fierce Pharma Asia-US Treasury homes in on China deals; Hengrui's secret sauce; Samsung Bio's strike developments | ||
| Do | Vabysmo shows signs of reacceleration as Roche gears up for busy 2027 | ||
| Do | AZ's Ultomiris adds 5th rare disease feather to cap with FDA IgAN nod | ||
| Do | Esteve earmarks $80M to revamp CDMO operations in China | ||
| Do | Pfizer's latest cost-savings plan looks to get early start as layoff reports surface around Europe, US plants | ||
| Do | Roivant comes for Humira as Lisraya checks boxes in inflammatory eye disease phase 3s | ||
| Do | FDA rebukes Baxter over 'repeated' production stumbles in new warning letter | ||
| Do | AI-Powered Brand Sites Are Changing Patient Engagement | ||
| Do | AbbVie pumps up the economic case for early subcutaneous Parkinson's treatment | ||
| Do | Otsuka hit with 11 marketing code breaches after event organizer blunder | ||
| 21.10. | New US drug launches need price check to counter access impediments, ICER, West Health urge | ||
| 21.10. | CSL taps GSK's Deborah Waterhouse as CEO in the darkest hour | ||
| 21.10. | Alcon ponies up $550M for Neurotech, bagging approved cell therapy implant Encelto | ||
| 21.10. | GSK brings promise of 'functional cure' to hepatitis B finish line with FDA nod for Hibsago | ||
| 20.10. | CDMO Samsung Bio wins temporary reprieve from strike threat after Seoul court ruling | ||
| 20.10. | Antheia lands $80M conditional loan from Trump administration to onshore drug manufacturing | ||
| 20.10. | Cosette lands FDA approval for Evoxac liquid in Sjögren's disease |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.